<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649216</url>
  </required_header>
  <id_info>
    <org_study_id>PCO006EU</org_study_id>
    <nct_id>NCT04649216</nct_id>
  </id_info>
  <brief_title>Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371</brief_title>
  <official_title>A Phase I, Single-Center, Open-Label Study Investigating the Excretion Balance, Pharmacokinetics (PK) and Metabolism of a Single Oral Dose of [14C]PCO371 and PK of an Intravenous (IV) Tracer of [14C]PCO371 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I single center, open-label, non-randomized study in healthy male subjects,&#xD;
      designed to evaluate the mass balance recovery, PK, metabolism and absolute bioavailability&#xD;
      of single oral doses of PCO371. It is planned to enroll 12 subjects, with 6 subjects in each&#xD;
      of 2 study parts. Subjects in Part 1 will receive a single oral dose of [14C]PCO371 Oral&#xD;
      Solution. Subjects in Part 2 will receive a single oral dose of PCO371 capsules, followed by&#xD;
      a single intravenous infusion of [14C]PCO371 Solution for Infusion over 10 min, starting 2 h&#xD;
      post-oral dose. The study parts may be dosed in any order for logistical reasons (e.g. Part 2&#xD;
      may be dosed before Part 1). No subject will be permitted to take part in both study parts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance data for [14C]PCO371 Oral solution in urine</measure>
    <time_frame>1 week</time_frame>
    <description>Amount of total radioactivity excreted in urine(Ae(urine)) and Ae(urine) expressed as a percentage of the radioactive dose administered (%Ae(urine)), cumulative amount of total radioactivity excreted in urine (CumAe(urine)) and CumAe(urine)expressed as a percentage of the radioactive dose administered (Cum%Ae(urine)) following oral administration of [14C]PCO371 Oral Solution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance data for [14C]PCO371 Oral solution in feces</measure>
    <time_frame>5 weeks</time_frame>
    <description>Amount of total radioactivity excreted in feces(Ae(feces)) and Ae(feces) expressed as a percentage of the radioactive dose administered (%Ae(feces)), cumulative amount of total radioactivity excreted in feces (CumAe(feces)) and CumAe(feces)expressed as a percentage of the radioactive dose administered (Cum%Ae(feces)) following oral administration of [14C]PCO371 Oral Solution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance data for [14C]PCO371 Oral solution in urine and feces combined</measure>
    <time_frame>5 weeks</time_frame>
    <description>Amount of total radioactivity excreted in urine and feces combined(Ae(total)) and Ae(total) expressed as a percentage of the radioactive dose administered (%Ae(total)), cumulative amount of total radioactivity excreted in urine and feces combined (CumAe(total)) and CumAe(total)expressed as a percentage of the radioactive dose administered (Cum%Ae(total)) following oral administration of [14C]PCO371 Oral Solution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute bioavailability (F) for PCO371</measure>
    <time_frame>1 week</time_frame>
    <description>Time of maximum observed concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; Tmax</measure>
    <time_frame>1 week</time_frame>
    <description>Time of maximum observed concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; Cmax</measure>
    <time_frame>1 week</time_frame>
    <description>Maximum observed concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; AUC(0-last)</measure>
    <time_frame>1 week</time_frame>
    <description>Area under the curve from time 0 to the time of last measurable concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; AUC(0-inf)</measure>
    <time_frame>1 week</time_frame>
    <description>Area under the curve from time 0 extrapolated to infinity for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; T1/2</measure>
    <time_frame>1 week</time_frame>
    <description>Terminal elimination half-life for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; Cmax ratio</measure>
    <time_frame>1 week</time_frame>
    <description>Ratio of PCO371: total radioactivity and ratio of a metabolite: total radioactivity based on Cmax following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; AUC ratio</measure>
    <time_frame>1 week</time_frame>
    <description>Ratio of whole blood: plasma total radioactivity based on Cmax following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; B:P Cmax ratio</measure>
    <time_frame>1 week</time_frame>
    <description>Ratio of whole blood:plasma total radioactivity based on Cmax following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic data for [14C]PCO371 Oral Solution; B:P AUC ratio</measure>
    <time_frame>1 week</time_frame>
    <description>Ratio of whole blood:plasma total radioactivity based on AUC following oral administration of [14C]PCO371 Oral Solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite profiling of plasma, urine and feces</measure>
    <time_frame>1 week</time_frame>
    <description>The chemical structure of each metabolite accounting for &gt;=5% of circulating radioactivity in plasma and accounting for &gt;=5% of the dose in the urine and feces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; C0</measure>
    <time_frame>1 week</time_frame>
    <description>Concentration at end of infusion of [14C]PCO371 and total radioactivity in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; AUC(0-last)</measure>
    <time_frame>1 week</time_frame>
    <description>Area under the curve from time 0 to the time of last measurable concentration of [14C]PCO371 and total radioactivity in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; AUC(0-inf)</measure>
    <time_frame>1 week</time_frame>
    <description>Area under the curve from time 0 extrapolated to infinity of [14C]PCO371 and total radioactivity in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; T1/2</measure>
    <time_frame>1 week</time_frame>
    <description>Terminal elimination half-life of [14C]PCO371 and total radioactivity in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; CL</measure>
    <time_frame>1 week</time_frame>
    <description>Total body clearance calculated after a single IV administration of [14C]PCO371 in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; Vz</measure>
    <time_frame>1 week</time_frame>
    <description>Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single IV administration of [14C]PCO371 in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetic data for PCO371 capsule; Tmax</measure>
    <time_frame>1 week</time_frame>
    <description>Time of maximum observed concentration for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetic data for PCO371 capsule; Cmax</measure>
    <time_frame>1 week</time_frame>
    <description>Maximum observed concentration for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetic data for PCO371 capsule; AUC(0-last)</measure>
    <time_frame>1 week</time_frame>
    <description>Area under the curve from time 0 to the time of last measurable concentration for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetic data for PCO371 capsule; AUC(0-inf)</measure>
    <time_frame>1 week</time_frame>
    <description>Area under the curve from time 0 extrapolated to infinity for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral pharmacokinetic data for PCO371 capsule; T1/2</measure>
    <time_frame>1 week</time_frame>
    <description>Terminal elimination half-life for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mass balance data for [14C]PCO371 Solution for Infusion in urine</measure>
    <time_frame>1 week</time_frame>
    <description>Cumulative amount of total radioactivity excreted in urine expressed as a percentage of the radioactive dose administered (Cum%Ae(urine)) and cumulative amount of [14C]PCO371 excreted in urine expressed as a percentage of the [14C]PCO371 dose administered (Cum%Ae([14C]PCO371 urine))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mass balance data for [14C]PCO371 Solution for Infusion in feces</measure>
    <time_frame>5 weeks</time_frame>
    <description>Cumulative amount of total radioactivity excreted in feces expressed as a percentage of the radioactive dose administered (Cum%Ae(feces)) and cumulative amount of [14C]PCO371 excreted in feces expressed as a percentage of the [14C]PCO371 dose administered (Cum%Ae([14C]PCO371 feces))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; Adverse event monitoring</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; Incidence of laboratory abnormalities</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence of laboratory abnormalities, based on clinical laboratory tests ( i.e. hematology, clinical chemistry, coagulation and urinalysis test results)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; 12-lead ECGs (Ventricular Rate)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Electrocardiograms (ECGs) Interpretation based on Ventricular Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; 12-lead ECGs (PR interval)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Electrocardiograms (ECGs) Interpretation based on PR interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; 12-lead ECGs (QRS Duration)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Electrocardiograms (ECGs) Interpretation based on QRS Duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; 12-lead ECGs (QT interval)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Electrocardiograms (ECGs) Interpretation based on QT interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; 12-lead ECGs (QRS Axis)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Electrocardiograms (ECGs) Interpretation based on QRS Axis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; 12-lead ECGs (QTcF interval)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Electrocardiograms (ECGs) Interpretation based on QTcF interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; 12-lead ECGs (Rhythm)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Electrocardiograms (ECGs) Interpretation based on Rhythm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; Vital signs (Systolic blood pressure)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; Vital signs (Diastolic blood pressure)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; Vital signs (Heart Rate)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Heart Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; Vital signs (Oral temperature)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Oral temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data for PCO371; Presense of abnormalities in Physical examinations</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormality in Physical examination findings</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Mass Balance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of [14C]PCO371 Oral Solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Absolute Bioavailability and Mass Balance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of PCO371 capsules, followed by a single IV infusion of [14C]PCO371 over 10 min, starting 2 h post-oral dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCO371</intervention_name>
    <description>PCO371 Capsule</description>
    <arm_group_label>Absolute Bioavailability and Mass Balance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]PCO371</intervention_name>
    <description>[14C]PCO371 Oral solution</description>
    <arm_group_label>Mass Balance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]PCO371</intervention_name>
    <description>[14C]PCO371 Solution for infusion</description>
    <arm_group_label>Absolute Bioavailability and Mass Balance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males&#xD;
&#xD;
          2. Aged 40 to 60 years inclusive at the time of signing informed consent.&#xD;
&#xD;
          3. Body mass index (BMI) of 18.5 to 30.0 kg/m2 as measured at screening.&#xD;
&#xD;
          4. Must be willing and able to communicate and participate in the whole study.&#xD;
&#xD;
          5. Subjects must have regular bowel movements (i.e. average stool production of &gt;=1 and&#xD;
             &lt;=3 stools per day).&#xD;
&#xD;
          6. Must provide written informed consent.&#xD;
&#xD;
          7. Must agree to adhere to the contraception requirements.&#xD;
&#xD;
          8. Subjects must regularly consume 2 or more units of alcohol per week.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have taken any experimental (non-approved) drug (including placebo)&#xD;
             either within 90 days before the administration of the study drug, or 6 times the T1/2&#xD;
             of the experimental drug, whichever is longer.&#xD;
&#xD;
          2. Subjects who have previously been administered IMP in this study. Subjects are not&#xD;
             permitted to be dosed in both Part 1 and Part 2 of the study.&#xD;
&#xD;
          3. Subjects who have been administered IMP in any 14C-labelled ADME in the last 12&#xD;
             months.&#xD;
&#xD;
          4. Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years.&#xD;
&#xD;
          5. No occupationally exposed worker, as defined in the Ionising Radiation Regulations&#xD;
             2017, shall participate in the study.&#xD;
&#xD;
          6. Subjects who do not have suitable veins for multiple venipunctures / cannulation as&#xD;
             assessed by the investigator or delegate at screening.&#xD;
&#xD;
          7. Clinically significant abnormal clinical chemistry, hematology, coagulation or&#xD;
             urinalysis as judged by the investigator at screening or admission.&#xD;
&#xD;
          8. Abnormal (outside of reference range) serum calcium or corrected calcium as measured&#xD;
             at admission or screening.&#xD;
&#xD;
          9. Elevated (&gt; 2.5 Ã— upper limit of normal [ULN]) alkaline phosphatase at admission or&#xD;
             screening. Subjects with Gilbert's syndrome or elevated (above the ULN) aspartate&#xD;
             aminotransferase (AST), ALT or total bilirubin at admission or screening.&#xD;
&#xD;
         10. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) antibody results.&#xD;
&#xD;
         11. Evidence of renal impairment at screening, as indicated by an estimated creatinine&#xD;
             clearance of &lt;60 mL/min using the Cockcroft-Gault equation.&#xD;
&#xD;
         12. Confirmed positive drugs of abuse test result.&#xD;
&#xD;
         13. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             or gastrointestinal disease, immunologic, metabolism, endocrine, neurological or&#xD;
             psychiatric disorder, as judged by the investigator, blood dyscrasia, risk factors for&#xD;
             osteosarcoma as judged by the investigator.&#xD;
&#xD;
         14. Evidence or any history of active diseases that might affect calcium, bone metabolism,&#xD;
             or calcium-phosphate homeostasis.&#xD;
&#xD;
         15. Use of anti-coagulants (e.g. heparins, warfarin, and thrombolytic agents),&#xD;
             anti-platelet medications (e.g. argatroban and ticlopidine), nonsteroidal&#xD;
             anti-inflammatory drugs and aspirin within 2 weeks (or within 6 times the T1/2 of the&#xD;
             drug, whichever is longer) prior to study drug administration.&#xD;
&#xD;
         16. Subjects who have taken any inducers of CYP3A4, P glycoprotein (e.g. St. John's wort),&#xD;
             or BCRP within 1 month prior to study drug administration, or taken any inhibitors of&#xD;
             CYP3A4, P-glycoprotein, or BCRP (including herbal products, diets, and drinks e.g.&#xD;
             tonic water) within 2 weeks prior to study drug administration (or within 6 times the&#xD;
             T1/2 of the drugs mentioned above, whichever is longer).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chugai Pharma Europe Ltd.</last_name>
    <role>Study Director</role>
    <affiliation>clinical-trials@chugai-pharm.co.jp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <state>UK</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

